SCHEMBL18003299

SCHEMBL18003299

CCc1oc(-c2ccc(Cl)cc2)nc1CO

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 3/20 0.46
HSD17B10 Q99714 1/20 0.45
TARBP2 Q15633 2/20 0.45
ALDH1A1 P00352 2/20 0.43
LMNA P02545 1/20 0.43
KDM4E B2RXH2 3/20 0.41
XBP1 P17861 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HPGD P15428 1/20 0.41
IKBKB O14920 1/20 0.40
POLB P06746 2/20 0.40
TP53 P04637 1/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
PPARA Q07869 2/20 0.39
PPARG P37231 1/20 0.39
UTRN P46939 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16398451 0.88 NOTUM (0.44) NOTUMHSD17B10TARBP2ALDH1A1LMNA
SCHEMBL9834911 0.88 HSD17B10 (0.48) NOTUMHSD17B10TARBP2ALDH1A1LMNA
SCHEMBL1930635 0.86 HSD17B10 (0.43) NOTUMHSD17B10TARBP2ALDH1A1LMNA
SCHEMBL18003020 0.85 POLB (0.44) NOTUMHSD17B10TARBP2ALDH1A1LMNA
SCHEMBL18003574 0.85 ALDH1A1 (0.45) NOTUMHSD17B10TARBP2ALDH1A1LMNA
SCHEMBL6604396 0.84 MEN1 (0.43) TARBP2ALDH1A1KDM4ENPSR1HPGD
SCHEMBL6606425 0.84 KDM4E (0.49) NOTUMHSD17B10TARBP2ALDH1A1KDM4E
SCHEMBL5762006 0.81 HSD17B10 (0.56) NOTUMHSD17B10TARBP2ALDH1A1LMNA
SCHEMBL9831245 0.78 KDM4E (0.52) NOTUMHSD17B10TARBP2ALDH1A1LMNA
SCHEMBL16399868 0.77 NOTUM (0.49) NOTUMHSD17B10TARBP2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 NOTUM 1379/4885HSD17B10 121/4885TARBP2 2133/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 NOTUM 1379/4885HSD17B10 121/4885TARBP2 2133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.